Lecture covers the pharmacology of anticholinergic drugs. Includes classification, therapeutic uses, adverse effects of anticholinergics. Atropine has been described as prototype drug.
Autacoids - pharmacological actions and drugs related to them. SIVASWAROOP YARASI
Autacoids or "autocoids" are biological factors which act like local hormones, have a brief duration, and act near the site of synthesis. The word autacoids comes from the Greek "autos" (self) and "acos" (relief, i.e. drug).
This presentation was delivered over two days to second year pharmacy students enrolled in a course in pharmacology & toxicology. This lecture is designed to accompany Goodman & Gilman's (12e) chapter 11.
Lecture covers the pharmacology of anticholinergic drugs. Includes classification, therapeutic uses, adverse effects of anticholinergics. Atropine has been described as prototype drug.
Autacoids - pharmacological actions and drugs related to them. SIVASWAROOP YARASI
Autacoids or "autocoids" are biological factors which act like local hormones, have a brief duration, and act near the site of synthesis. The word autacoids comes from the Greek "autos" (self) and "acos" (relief, i.e. drug).
This presentation was delivered over two days to second year pharmacy students enrolled in a course in pharmacology & toxicology. This lecture is designed to accompany Goodman & Gilman's (12e) chapter 11.
Med chem lecture on Anticholinergic drugs for B.Pharm level in Nepal
Content from Foye's Principle of medicinal chemistry, my own thoughts and some articles
Adrenergic Agonist & Sympathomimetic Drugs.
It includes:
Sympathetic Nervous System
Structures of the major catecholamines
Drugs acting at adrenergic neurons
Structure-Activity Relationship of sympathomimetic Amines
Structure & main clinical use of important sympathomimetic drugs
Adrenergic Receptors: Types, Nomenclature
Sympathomimetic drugs (with Recent Advances)
Beta-adrenergic blockers as a potential treatment for COVID-19 patients
Summary
A Power point presentation on Betalactam antibiotics suitable for undergraduate medical students. This Ppt is already presented in theory class lectures to the students of NEIGRIHMS, Shillong, Meghalaya
A Powerpoint presentation on drugs excretion and elimination suitable for UG medical students. This ppt is already presented to my students in one of the theory classes.
A PowerPoint presentation on "NSAIDS" suitable for reading by UG and PG Medical/Paramedical students of Pharmacology and Pharmacy sciences. This Ppt. is prepared for academic purpose only and already presented to my students in one of the theory classes of mine.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
3. Noradrenergic transmission
Nor-adrenaline is the major
neurotransmitter of the
Sympathetic system
Noradrenergic neurons are
postganglionic sympathetic
neurons with cell bodies in
the sympathetic ganglia
They have long axons
which end in varicosities
where NA is synthesized
and stored
4. Adrenergic transmission
Catecholamines:
Natural: Adrenaline, Noradrenaline, Dopamine
Synthetic: Isoprenaline, Dobutamine
Non-Catecholamines:
Ephedrine, Amphetamines, Phenylepherine, Methoxamine,
Mephentermine
Also called sympathomimetic amines as most of them
contain an intact or partially substituted amino (NH2)
group
5. • Catecholamines:
Compounds containing
a catechol nucleus
(Benzene ring with 2
adjacent OH groups)
and an amine
containing side chain
• Non-catecholamines
lack hydroxyl (OH)
group
11. Reuptake
Sympathetic nerves take up amines and release
them as neurotransmitters
Uptake I is a high efficiency system more specific
for NA
Located in neuronal membrane
Inhibited by Cocaine, TCAD, Amphetamines
Uptake 2 is less specific for NA
Located in smooth muscle/ cardiac muscle
Inhibited by steroids/ phenoxybenzamine
No Physiological or Pharmacological importance
12. Metabolism of CAs
Mono Amine Oxidase (MAO)
Intracellular bound to mitochondrial membrane
Present in NA terminals and liver/ intestine
MAO inhibitors are used as antidepressants
Catechol-o-methyl-transferase (COMT)
Neuronal and non-neuronal tissue
Acts on catecholamines and byproducts
VMA levels are diagnostic for tumours
16. Adrenergic Receptors
Adrenergic receptors (or adrenoceptors) are a class of G-protein
coupled receptors that are the target of catecholamines
Adrenergic receptors specifically bind their endogenous ligands –
catecholamines (adrenaline and noradrenline)
Increase or decrease of 2nd messengers cAMP or IP3/DAG
Many cells possess these receptors, and the binding of an
agonist will generally cause the cell to respond in a flight-fight
manner.
For instance, the heart will start beating quicker and the pupils
will dilate
17. How Many of them ????
Adenoreceptors
Alpha (α) Beta (β)
α 1 α 2 β1 β 2 β3
α 2A α 2B α 2C
α 1A α 1B α 1D
18. Differences - Adrenergic
Receptors (α and β) !
Alpha (α) and Beta (β)
Agonist affinity of alpha (α):
adrenaline > noradrenaline > isoprenaline
Antagonist: Phenoxybenzamine
IP3/DAG, cAMP and K+ channel opening
Agonist affinity of beta (β):
isoprenaline > adrenaline > noradrenaline
Propranolol
cAMP and Ca+ channel opening
19. Potency of catecholamines on
Adrenergic Receptors
Aortic strip contraction Bronchial relaxation
Adr NA
α β
Iso
Iso Adr
NA
Log Concentration
21. Recall: Adenylyl cyclase: cAMP
pathway
PKA alters the functions of many
Enzymes, ion channels,
transporters
and structural proteins.
PKA Phospholamban
Increased
Interaction with
Ca++
Faster relaxation
Troponin
Cardiac
contractility
Other
Functional
proteins
Faster sequestration of
Ca++ in SR
23. Beta receptors
All β receptors activate adenylate cyclase, raising the intracellular cAMP
concentration
Type β1:
These are present in heart tissue, and cause an increased heart rate by
acting on the cardiac pacemaker cells
Type β2:
These are in the vessels of skeletal muscle, and cause vasodilatation, which
allows more blood to flow to the muscles, and reduce total peripheral
resistance
Beta-2 receptors are also present in bronchial smooth muscle, and cause
bronchodilatation when activated
Stimulated by adrenaline, but not noradrenaline
Bronchodilator salbutamol work by binding to and stimulating the β2
receptors
Type β3:
Beta-3 receptors are present in adipose tissue and are thought to have a
role in the regulation of lipid metabolism
24. Differences between β1, β2 and β3
Beta-1 Beta-2 Beta-3
Location Heart and JG cells Bronchi, uterus,
Blood vessels,
liver, urinary tract,
eye
Adipose
tissue
Agonist Dobutamine Salbutamol -
Antagonist Metoprolol, Atenolol Alpha-methyl
propranolol
-
Action on
NA
Moderate Weak Strong
25. Clinical Effects of β-receptor
stimulation
β1: Adrenaline, NA and Isoprenaline:
Tachycardia
Increased myocardial contractility
Increased Lipolysis
Increased Renin Release
β2: Adrenaline and Isoprenaline (not NA)
Bronchi – Relaxation
SM of Arterioles (skeletal Muscle) – Dilatation
Uterus – Relaxation
Skeletal Muscle – Tremor
Hypokalaemia
Hepatic Glycogenolysis and hyperlactiacidemia
β3: Increased Plasma free fatty acid – increased O2 consumption -
increased heat production
26. Adrenergic receptors - alpha
Type α1
Blood vessels with alpha-1 receptors are present in the
skin and the genitourinary system, and during the fight-or-flight
response there is decreased blood flow to these
organs
Acts by phospholipase C activation, which forms IP3 and
DAG
In blood vessels these cause vasoconstriction
Type α2
These are found on pre-synaptic nerve terminals
Acts by inactivation of adenylate cyclase, cyclic AMP levels
within the cell decrease (cAMP)
27. Differences between α1 and α2
Alpha-1 Alpha-2
Location Post junctional – blood vessels
of skin and mucous
membrane, Pilomotor muscle
& sweat gland, radial muscles
of Iris
Prejunctional
Function Stimulatory – GU,
Vasoconstriction, gland
secretion, Gut relaxation,
Glycogenolysis
Inhibition of transmitter
release, vasoconstriction,
decreased central symp.
Outflow, platelet
aggregation
Agonist Phenylephrine, Methoxamine Clonidine
Antagonist Prazosin Yohimbine
29. Molecular Basis of Adrenergic
Receptors
Also glycogenolysis
in liver
Inhibition of
Insulin
release and
Platelet
aggregation
Gluconeogen
esis
30. Dopamine receptors
D1-receptors are post synaptic receptors
located in blood vessels and CNS
D2-receptors are presynaptic present in CNS,
ganglia, renal cortex
31. Summary of agents modifying
adrenergic transmission
Step Actions Drug
Synthesis of NA Inhibition α - methyl-p-tyrosine
Axonal uptake Block Cocaine, guanethidine,
ephedrine
Vesicular uptake Block Reserpine
Vesicular NA Displacement Guanethidine
Membrane NA pool Exchange diffusion Tyramine, Ephedrine
Metabolism MAO-A inhibition
MAO-B inhibition
COMT inhibition
Moclobemide
Selegiline
Tolcapone
Receptors α 1
α 2
β1 + β2
β1
Prazosin
Yohimbine
Propranolol
Metoprolol
32.
33. Adrenaline as prototype
Potent stimulant of alpha and beta receptors
Complex actions on target organs
34. Heart
Beta-1 mediated action - Powerful Cardiac stimulant - +ve
chronotropic, +ve inotropic
Acts on beta-1 receptors in myocardium, pacemaker cells and
conducting tissue
Heart rate increases by increasing slow diastolic depolarization of cells
in SAN
High doses cause marked rise in heart rate and BP causing reflex
depression of SAN – unmasking of latent pacemaker cells in AVN and
PF – arrhythmia (sensitization of arrhythmogenic effects by Halothane)
Cardiac systole is shorter and more powerful
Cardiac output is enhanced and Oxygen consumption is increased
Cardiac efficiency is markedly decreased
Conduction velocity in AVN, atrial muscle fibre, ventricular fibre and
Bundle of His increased – benefit in partial AV block
Reduced refractory period in all cardiac cells
35. Blood Vessels
Seen mainly in the smaller vessels –
arterioles – Vasoconstriction (alpha) and
vasodilatation (beta) – depends on the drug
Decreased blood flow to skin and mucus
membranes and renal beds – alpha effect (1
and 2) -
Increased blood flow to skeletal muscles,
coronary and liver vessels - (Beta-2 effect)
counterbalanced by a vasoconstrictor effect
of alpha receptors
36. Blood Pressure
Depends on the Catecholamine involved
NA causes rise in Systolic, diastolic and mean
BP (no beta-2 action) – unopposed alpha action
Isoprenaline causes rise in systolic but fall in
diastolic BP – mean BP falls (beta-1 and beta-2)
Adr causes rise in systolic BP, but fall in diastolic
BP – mean BP generally rises (slow injection)
Decreased peripheral resistance at low conc. Beta
receptors are more sensitive to Adr than alpha
receptors
37. Blood Pressure – contd.
Rapid IV injection of Adrenaline marked rise in
Systolic and diastolic BP
Large concentration alpha action predominates –
vasoconstriction even in skeletal muscle
But BP returns to normal in few minutes
A secondary fall in mean BP occurs
Mechanism – rapid uptake and dissipation of
Adr – at low conc. Alpha action lost but beta
action predominates – Dale`s Vasomotor
reversal phenomenon
39. Actions of Adrenaline
Respiratory:
Powerful bronchodilator
Relaxes bronchial smooth muscle (not NA)
Beta-2 mediated effect
Physiological antagonist to mediators of
bronchoconstriction e.g. Histamine
GIT : Relaxation of gut muscles (alpha and beta) and constricted
sphincters – reduced peristalsis – not clinical importance
Bladder: relaxed detrusor muscle (beta) muscle but constriction of
Trigone – both are anti-voiding effect
Uterus: Adr contracts and relaxes Uterus (alpha and beta action)
but net effect depends on status of uterus and species – pregnant
relaxes but non-pregnant - contracts
40. Actions of Adrenaline – contd.
Skeletal Muscle:
Facilitation of Ach release in NM junction (alpha -1)
Beta-2 acts directly on Muscle fibres
Abbreviated active state and less tension in slow
conducting fibres and enhanced muscle spindle firing
– tremor
CNS: No visible clinical effect in normal doses – as low
penetration except restlessness, apprehension and
tremor
Activation of alpha-2 in CNS decreases sympathetic outflow and
reduction in BP and bradycardia - clonidine
41. Metabolic effects
Increases concentration of glucose and lactic
acid
Calorigenesis (β-2 and β-3)
Inhibits insulin secretion (α-2)
Decreases uptake of glucose by peripheral
tissue
Simulates glycogenolysis - Beta effect
Increases free fatty acid concentration in blood
Hypokalaemia – initial hyperkalaemia
42. ADME
All Catecholamines are ineffective orally
Absorbed slowly from subcutaneous tissue
Faster from IM site
Inhalation is locally effective
Not usually given IV
Rapidly inactivated in Liver by MAO and
COMT
43. Clinical Question!
Question: A Nurse was injecting a dose of penicillin
to a patient in Medicine ward without prior skin test
and patient suddenly developed immediate
hypersensitivity reactions. What would you do?
Answer: As the patient has developed Anaphylactic
reaction, the only way to resuscitate the patient is
injection of Adrenaline
0.5 mg (0.5 ml of 1:10000) IM and repeat after 5-10
minutes
Antihistaminics: Chlorpheniramine 10 – 20 mg IM or IV
Hydrocortisone 100 – 200 mg
44. Adrenaline – Clinical uses
Injectable preparations are available in dilutions
1:1000, 1:10000 and 1:100000
Usual dose is 0.3-0.5 mg sc of 1: 10000 solution
Used in:
Anaphylactic shock…
Prolong action of local anaesthetics
Cardiac arrest
Topically, to stop bleeding
Hyperkinetic children – ADHD, minimal brain dysfunction
Anorectic
48. Noradrenaline
Neurotransmitter released from
postganglionic adrenergic nerve endings
(80%)
Orally ineffective and poor SC absorption
IV administered
Metabolized by MAO, COMT
Short duration of action
49. Actions and uses
Agonist at α1(predominant), α2 and β1 Adrenergic receptors
Equipotent with Adr on β1, but No effect on β2
Increases systolic, diastolic B.P, mean pressure, pulse pressure
and stroke volume
Total peripheral resistance (TPR) increases due to vasoconstriction -
Pressor agent
Increases coronary blood flow
Decreases blood flow to kidney, liver and skeletal muscles
Uses: Injection Noradrenal bitartrate slow IV infusion at the rate
of 2-4mg/ minute used as a vasopressor agent in treatment of
hypovolemic shock and other hypotensive states in order to raise
B.P
Problems: Down regulation of receptors, Renal Vasoconstriction
Septic and neurogenic shock (?)
50. Noradrenaline - ADRs
Anxiety, palpitation, respiratory difficulty
Acute Rise of BP, headache
Extravasations causes necrosis, gangrene
Contracts gravid uterus
Severe hypertension, violent headache,
photophobia, anginal pain, pallor and
sweating in hyperthyroid and hypertensive
patients
51. Isoprenaline
Catecholamine acting on beta-1 and beta-2 receptors – negligible
action on alpha receptor
Therefore main action on Heart and muscle
vasculature
Main Actions: Fall in Diastolic pressure, Bronchodilatation and
relaxation of Gut
ADME: Not effective orally, sublingual and inhalation (10mg tab. SL)
Overall effect is Cardiac stimulant (beta-1)
Increase in SBP but decrease in DBP (beta-2)
Decrease in mean BP
Used as Bronchodilator and for treatment of AV block, Stokes-Adam
Syndrome etc. – but not preferred anymore
53. Dopamine
Immediate metabolic precursor of
Noradrenalin
High concentration in CNS - basal ganglia,
limbic system and hypothalamus and also in
Adrenal medulla
Central neurotransmitter, regulates body
movements ineffective orally, IV use only,
Short T 1/2 (3-5minutes)
54. Dopamine
MECHANISM:
Agonists at dopaminergic D1, D2 receptors
Agonist at adrenergic α1 and β1
55. Dopamine
In small doses 2-5 μg/kg/minute, it stimulates D1-
receptors in renal, mesenteric and coronary vessels
leading to vasodilatation (Increase in cAMP)
Recall: Renal vasoconstriction occurs in CVS shock due to
sympathetic over activity
Increases renal blood flow, GFR an causes natriuresis
Interaction with D2 receptors (present in presynaptic adrenergic
neurones) – suppression of NA release (no alpha effect)
56. Dopamine – cond.
Moderate dose (5-10 μg/kg/minute), stimulates β1-
receptors in heart producing positive inotropic and
chronotropic actions actions
Releases Noradrenaline from nerves by β1-
stimulation
Does not change TPR and HR
Great Clinical benefit in CVS shock and CCF
High dose (10-30 μg/kg/minute), stimulates vascular
adrenergic α1-receptors (NA release) –
vasoconstriction and decreased renal blood flow
57. Why renal and mesenteric
vasodilatation is useful in Shock?
Increases renal blood flow, GFR an
causes natriuresis
In CVS shock – excessive sympathetic
activity leading to ischemia of gut,
sloughening and entry of Bacteria to
systemic circulation - septicemia
58. Dobutamine - Derivative of
Dopamine
MOA:
Acts on both alpha and beta receptors but more prominently in beta-1
receptor – increase in contractility and CO
Does not act on D1 or D2 receptors – No release of NA and thereby
hypertension
Predominantly a beta-1 agonist with weak beta-2 and selective alpha-1
activity
Racemic mixture consisting of both (+) and (−) isomers - the (+) isomer
is a potent β1 agonist and α1 antagonist, while the (−) isomer is an α1
agonist
Overall beta-1 activity and weak beta-2 activity
Increase in force of contraction and cardiac output but no change in
heart rate
Uses: Clinically give in dose of 2-8 mcg/kg/min IV infusion in Heart
failure in cardiac surgery, Septic and cardiogenic shock, Congestive Heart
failure
ADRs: Tachycardia, hyperension, angina and fatal arrhythmia
61. Ephedrine
Plant alkaloid obtained from Ephedra vulgaris – Mixed acting drug
(also metaraminol) – effective orally
Crosses BBB and Centrally – Increased alertness, anxiety,
insomnia, tremor and nausea in adults. Sleepiness in children
Effects appear slowly but lasts longer (t1/2-4h) – 100 times less
potent
Tachyphylaxis on repeated dosing (low neuronal pool)
Used as bronchodilator, mydriatic, in heart block, mucosal
vasoconstriction & in myasthenia gravis
Not used commonly due to non-specific action
Uses: Mild Bronchial asthma, hypotension due to spinal anaesthesia
Available as tablets, nasal drop and injection
62. Phenylepherine - Selective,
synthetic and direct α1 agonist
Actions qualitatively similar to noradrenaline
Long duration of action
Resistant to MAO and COMT
Does not cross BBB, so no CNS effects
Peripheral vasoconstriction leads to rise in BP but Reflex
bradycardia
Produces mydriasis and nasal decongestion
Use:
hypovolaemic shock as pressor agent
Sinusitis & Rhinitis as nasal decongestant (common in oral preparations)
Mydriatic in the form of eye drops and lowers intraocular pressure
ADRs: Photosensitivity, conjunctival hyperemia and hypersensitivity
Administered parenteraly & topically (eye, nose)
63. What are Mucosal Decongestants?
Nasal and bronchial decongestants are the drugs used
in allergic rhinitis, colds, coughs and sinusitis as nasal
drops - Sympathomimetic vasoconstrictors with α-
effects are used
Drugs: Phenylepherine, xylometazoline, Oxymetazoline,
PPA, Pseudoephidrine etc.
Drawbacks:
Rebound congestion due to overuse
However, mucosal ischaemic damage occurs if used excessively
(more often than 3 hrly) or for prolonged periods (>3weeks)
CNS Toxicity
Failure of antihypertensive therapy
Fatal hypertensive crisis in patients on MAOIs
Use only a few days since longer application reduces ciliary action
64. Nasal Decongestants
Pseudoephedrine to Ephedrine but less CNS and Cardiac
effects
Poor Bronchodilator
Given in combination with antihistaminics, antitussives and NSAIDs
in common cold and, allergic rhinitis, blocked Eustachian tube etc.
Rise in BP inhypertensives
Phenylpropanolamine (PPA) is similar to ephedrine and used
as decongestants in many cold and cough preparations
Also as weight loosing agent
Xylometazoline, Oxymetazoline etc.
65. Amphetamine
Synthetic compound similar to Ephedrine Pharmacologically
Known because of its CNS stimulant action – psychoactive drug and
also performance enhancing drug
Actions:
alertness, euphoria, talkativeness and increased work capacity – fatigue
is allayed (acts on DA and NA neurotransmitters etc. –reward pathway)
increased physical performance without fatigue – short lasting (Banned
drug and included in the list of drugs of “Dope Test)” – deterioration
occurs
RAS Stimulation – wakefulness, sleep deprivation (then physical
disability)
However, anxiety, restlessness, tremor and dysphoria occurs
Other actions: Stimulation of respiratory centre, Hunger
suppression, also anticonvulsant, analgesic and antiemetic
actions
66. Amphetamine – contd.
Drug of abuse – marked psychological effect but little
physical dependence
Generally, Teenage abusers - thrill or kick
High Dose – Euphoria, excitement and may progress to
delirium, hallucination and acute psychotic state
Also peripheral effects like arrhythmia, palpitation, vascular
collapse etc.
Repeated Dose – Long term behavioural abnormalities
Starvation – acidic urine
Uses: Hyperkinetic Children (ADHD), Narcolepsy,
Epilepsy and Parkinsonism
67. Anorectics
Drugs used for suppression of appetite
MOA: Inhibition of NA/DA or 5-HT uptake –
enhancement of monoaminergic transmission
NA agents affect the appetite centre and
Serotonergics act on satiety centre
Fenfluramine, dexfenfluramine and
sibutramine – ALL ARE BANNED NOW
Reasons: Heart valve defects, fibrosis and
pulmonary hypertension etc.
68. Clonidine
Centrally acting: Agonist to postsynaptic α2A
adrenoceptors in brain – vasomotor centre in
brainstem (presynaptic Ca++ level – increased NA
release)
Decrease in BP and cardiac output
Peripherally action: High dose activates peripheral
presynaptic autoreceptors on adrenergic nerve
ending mediating negative feedback suppression of
noradrenaline release
Overdose stimulates peripheral postsynaptic α1
adrenoceptors & cause hypertension by
vasoconstriction
69. Clonidine – contd.
Uses: ADHD in children, opioid withdrawal (restless legs, jitters and
hypertension), alcohol withdrawal (0.3 to 0.6 mg)
Abrupt or gradual withdrawal causes rebound hypertension
Onset may be rapid (a few hours) or delayed for as long as 2 days and
subsides over 2-3 days
Never use beta-blockers to treat
Available as tablets, injections and patches
Sedation, dry mouth, dizziness and constipation etc.
TCAs antagonize antihypertensive action & increase rebound
hypertension of abrupt withdrawal
Low dose Clonidine (50-100μg/dl) is used in migraine prophylaxis,
menopausal flushing and chorea
Moxonidine, Rilmenidine – Newer Imidazolines
70. β2 Adrenergic Agonists –
discussed elsewhere!
Short acting : Salbutamol, Metaproterenol, Terbutaline,
pirbuterol
Selective for β2 receptor subtype
Used for acute inhalational treatment of bronchospasm.
Onset of action within 1 to 5 minutes
Bronchodilatation lasts for 2 to 6 hours
Duration of action longer on oral administration
Directly relax airway smooth muscle
Relieve dyspnoea of asthmatic bronchoconstriction
Long acting: Salmeterol, Bitolterol, colterol
71. Uterine Relaxants - discussed
elsewhere!
Antioxytocics or tocolytic agents
β2 agonists relax uterus
Used by i.v. infusion to inhibit premature labour
Isoxsuprine, Terbutaline, Ritodrine, Salbutamol
Tachycardia & hypotension occur
Use minimum fluid volume using 5% dextrose as
diluents
Ritodrine: 50 μg/min, increase by 50 μg/min every
10 minutes until contractions stop or maternal heart
rate is 140 beats/minute. Continue for 12-48 hours
after contractions stop
72. Remember ?
Steps of Biosynthesis of Catecholamine
Distribution of adrenergic receptors
Individual Functions of Adrenergic receptors
All aspects of adrenaline – Dale`s
Phenomenon
Dopamine/Dobutamine actions
Nasal decongestants - Phenylephrine
Amphetamine and Clonidine - Desirable